PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19034-2 1977 Titration studies of angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) were also made, whose results indicated a flexible folded conformation similar to that previously proposed for the octapeptide angiotensin II, with a possible additional beta turn at the C terminus. Leucine 72-75 angiotensinogen Homo sapiens 21-34 27591418-10 2016 Furthermore, the values obtained from the present method were in agreement with the result from isotope dilution quantification using isotopically labeled angiotensin I [Asp-Arg-(Val-d8 )-Tyr-Ile-His-Pro-(Phe-d8 )-His-Leu]. Leucine 218-221 angiotensinogen Homo sapiens 155-168 30620754-2 2019 Activation of PPARdelta by GW501516, a specific ligand of PPARdelta, significantly inhibited Ang II-stimulated protein synthesis in a concentration-dependent manner, as determined by [3H]-leucine incorporation. Leucine 188-195 angiotensinogen Homo sapiens 93-99 17261087-3 2007 Mutant angiotensinogens in which the Ile-His-Pro-Phe-His-Leu sequence at positions 5-10 of wild-type angiotensinogen was replaced by either His-Pro-Phe-His-Leu-Leu or Ala-Ile-His-Pro-Phe-His were cleaved by renin at the C-terminal side of residues 9 and 11, respectively, while wild-type angiotensinogen was cleaved at residue 10. Leucine 156-159 angiotensinogen Homo sapiens 7-22 21097843-12 2011 Finally, EEA1 down-regulation or expression of a dominant negative mutant of PKC-alpha blunts Ang II-induced leucine incorporation in VSMCs. Leucine 109-116 angiotensinogen Homo sapiens 94-100 19940161-7 2010 We demonstrate that overexpression of the phosphorylation-defective mutant PGC-1 alpha (S570A) prevents Ang II-induced increases in H(2)O(2) levels and hypertrophy ([(3)H]leucine incorporation). Leucine 171-178 angiotensinogen Homo sapiens 104-110 20980790-5 2010 An HSP90 inhibitor, geldanamycin (GA), significantly suppressed angiotensin II-induced [3H]leucine incorporation and atrial natriuretic factor expression in cardiac cells. Leucine 91-98 angiotensinogen Homo sapiens 64-78 17261087-3 2007 Mutant angiotensinogens in which the Ile-His-Pro-Phe-His-Leu sequence at positions 5-10 of wild-type angiotensinogen was replaced by either His-Pro-Phe-His-Leu-Leu or Ala-Ile-His-Pro-Phe-His were cleaved by renin at the C-terminal side of residues 9 and 11, respectively, while wild-type angiotensinogen was cleaved at residue 10. Leucine 57-60 angiotensinogen Homo sapiens 7-22 17261087-3 2007 Mutant angiotensinogens in which the Ile-His-Pro-Phe-His-Leu sequence at positions 5-10 of wild-type angiotensinogen was replaced by either His-Pro-Phe-His-Leu-Leu or Ala-Ile-His-Pro-Phe-His were cleaved by renin at the C-terminal side of residues 9 and 11, respectively, while wild-type angiotensinogen was cleaved at residue 10. Leucine 156-159 angiotensinogen Homo sapiens 7-22 14716206-4 2004 In the present study, we show that EGCG inhibits Ang II-stimulated VSMC hypertrophy, as determined by [3H]leucine incorporation into VSMC. Leucine 106-113 angiotensinogen Homo sapiens 49-55 17145192-5 2007 gACE was potently inhibited by EDTA, 1,10-phenanthroline, captopril and lisinopril, and it promptly released the dipeptides His-Leu and Phe-Arg from angiotensin I and bradykinin. Leucine 128-131 angiotensinogen Homo sapiens 149-162 15591230-13 2005 Ang II-induced DNA and protein synthesis, measured by 3[H]-thymidine and 3[H]-leucine incorporation, respectively, were increased in control and nonsilencing cells, but not in TRPM7 knockdown VSMCs. Leucine 78-85 angiotensinogen Homo sapiens 0-6 14977877-7 2004 Serum, thrombin, and angiotensin II likewise stimulated L-leucine transport by inducing LAT1 expression. Leucine 56-65 angiotensinogen Homo sapiens 21-35 16641152-6 2006 Ang II-induced mammalian target of rapamycin activation, [3H]leucine incorporation, and cellular hypertrophy were inhibited by pretreatment with either batimastat or CRM197 or by pretreatment with rapamycin or the EGFR tyrosine kinase inhibitor AG1478. Leucine 61-68 angiotensinogen Homo sapiens 0-6 9734602-10 1998 Ang II dose dependently increased MC 3H-leucine incorporation, and MC protein content, two markers of MC hypertrophy, as well as 3H-thymidine incorporation, a marker of MC hyperplasia. Leucine 40-47 angiotensinogen Homo sapiens 0-6 14583661-7 2003 The effect of anti-CTGF on Ang II (10(-7)M)-induced [(3)H]-leucine incorporation, total protein content (Coomassie brilliant blue G250 method) and change in cellular size [determined by a scanning electronic microscope (SEM)] was also observed. Leucine 59-66 angiotensinogen Homo sapiens 27-33 14583661-10 2003 Stimulation of cells with Ang II (10(-7)M) for 48 h resulted in a 92% increase in [(3)H]-leucine incorporation (5,584 cpm/10(5) cells at 0 h vs. 10,741 cpm/10(5) cells at 48 h; p = 0.01), which was significantly abolished by treatment with anti-CTGF antibody. Leucine 89-96 angiotensinogen Homo sapiens 26-32 11758242-7 2001 MC stimulated by Ang II revealed hypertrophy as well as increased [3H] leucine incorporation, decreased [3H] thymidine incorporation and increased ECM. Leucine 71-78 angiotensinogen Homo sapiens 17-23 10428852-7 1999 In VSMCs infected with dominant-negative Akt/PKB, angiotensin II-stimulated [(3)H]leucine incorporation is attenuated. Leucine 82-89 angiotensinogen Homo sapiens 50-64 11228745-6 1999 In these cells, or in cells in which NADH/NADPH oxidase activity is inhibited by diphenylene iodonium, angiotensin II-induced [3H]leucine incorporation is also inhibited. Leucine 130-137 angiotensinogen Homo sapiens 103-117 10419063-10 1999 Ang II also stimulated 3H-leucine incorporation in cells from aorta (Emax = 162 +/- 11.6 of control) and resistance arteries (Emax 175 +/- 10% of control). Leucine 26-33 angiotensinogen Homo sapiens 0-6 10453550-3 1997 When verapamil, EG-TA, dantrolene, and Fura-2/AM, were added to the medium, the 3H-leucine incorporations stimulated by Ang II were reduced by 17%, 19%, 22%, and 27%. Leucine 83-90 angiotensinogen Homo sapiens 120-126 10453550-4 1997 Using calcium ionophore-A23187 did not stimulate protein synthesis, but enhanced Ang II-induced 3H-leucine incorporation. Leucine 99-106 angiotensinogen Homo sapiens 81-87 8836769-10 1996 A dipeptide His-Leu carboxy-extension form of AII, angiotensin I (AI), only bound to anti-AII abs at 100-200 times higher concentrations, showing that the C-terminal epitope was blocked by the dipeptide. Leucine 16-19 angiotensinogen Homo sapiens 46-49 8817875-1 1996 Angiotensin-converting enzyme (ACE; EN 3.4.15.1) is a peptidyl dipeptide hydrolase that removes the carboxyl terminal His-Leu from angiotensin I to produce the octapeptide angiotensin II. Leucine 122-125 angiotensinogen Homo sapiens 131-144 8817875-1 1996 Angiotensin-converting enzyme (ACE; EN 3.4.15.1) is a peptidyl dipeptide hydrolase that removes the carboxyl terminal His-Leu from angiotensin I to produce the octapeptide angiotensin II. Leucine 122-125 angiotensinogen Homo sapiens 172-186 8836769-10 1996 A dipeptide His-Leu carboxy-extension form of AII, angiotensin I (AI), only bound to anti-AII abs at 100-200 times higher concentrations, showing that the C-terminal epitope was blocked by the dipeptide. Leucine 16-19 angiotensinogen Homo sapiens 51-64 8836769-10 1996 A dipeptide His-Leu carboxy-extension form of AII, angiotensin I (AI), only bound to anti-AII abs at 100-200 times higher concentrations, showing that the C-terminal epitope was blocked by the dipeptide. Leucine 16-19 angiotensinogen Homo sapiens 90-93 2175370-3 1990 In addition, there is mounting evidence, collected mostly in experiments in vitro, that other enzymes may be able to activate angiotensin I, for example by the stepwise release of the C-terminal His and Leu residues. Leucine 203-206 angiotensinogen Homo sapiens 126-139 1797705-1 1991 The N-terminal heptadecapeptide of human angiotensinogen (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Asn-Glu-Ser-Thr-NH2 ), with the C-terminal carboxyl group amidated, was synthesized in order to study the role of Asn-Glu-Ser, a putative carbohydrate binding site, on the hydrolysis by human renin. Leucine 94-97 angiotensinogen Homo sapiens 41-56 1894611-1 1991 We have recently identified and characterized a chymotrypsin-like serine proteinase in human heart (human heart chymase) that is the most catalytically efficient enzyme described, thus far, for the cleavage of angiotensin I to yield angiotensin II and the dipeptide His-Leu. Leucine 270-273 angiotensinogen Homo sapiens 210-223 1894611-1 1991 We have recently identified and characterized a chymotrypsin-like serine proteinase in human heart (human heart chymase) that is the most catalytically efficient enzyme described, thus far, for the cleavage of angiotensin I to yield angiotensin II and the dipeptide His-Leu. Leucine 270-273 angiotensinogen Homo sapiens 233-247 7848276-2 1995 In contrast, cells treated with angiotensin II had no significant increase in [3H]thymidine incorporation, but demonstrated a marked increase in [3H]leucine incorporation. Leucine 149-156 angiotensinogen Homo sapiens 32-46 1524216-3 1992 The hydrolysis of Abz-His-Pro-Phe-His-Leu-Val-Ile-His-EDDnp by human renin was inhibited by a highly specific transition-state analog of angiotensinogen (IC50 = 7.8 x 10(-9) M), described by K. Iizuka et al. Leucine 38-41 angiotensinogen Homo sapiens 137-152 1316850-1 1992 Angiotensin-I-converting enzyme (ACE) is a peptidyl-dipeptide hydrolase which splits off the dipeptide His-Leu from the decapeptide angiotensin I and thus converts it to angiotensin II. Leucine 107-110 angiotensinogen Homo sapiens 132-145 1316850-1 1992 Angiotensin-I-converting enzyme (ACE) is a peptidyl-dipeptide hydrolase which splits off the dipeptide His-Leu from the decapeptide angiotensin I and thus converts it to angiotensin II. Leucine 107-110 angiotensinogen Homo sapiens 170-184 1918036-1 1991 Human heart chymase, a chymotrypsin-like serine proteinase that hydrolyzes the Phe8-His9 bond in angiotensin I (Ang I) to yield the octapeptide hormone angiotensin II (Ang II) and His-Leu, is the most specific, efficient Ang II-forming enzyme described. Leucine 184-187 angiotensinogen Homo sapiens 97-110 1918036-1 1991 Human heart chymase, a chymotrypsin-like serine proteinase that hydrolyzes the Phe8-His9 bond in angiotensin I (Ang I) to yield the octapeptide hormone angiotensin II (Ang II) and His-Leu, is the most specific, efficient Ang II-forming enzyme described. Leucine 184-187 angiotensinogen Homo sapiens 112-117 1918036-1 1991 Human heart chymase, a chymotrypsin-like serine proteinase that hydrolyzes the Phe8-His9 bond in angiotensin I (Ang I) to yield the octapeptide hormone angiotensin II (Ang II) and His-Leu, is the most specific, efficient Ang II-forming enzyme described. Leucine 184-187 angiotensinogen Homo sapiens 152-166 1918036-1 1991 Human heart chymase, a chymotrypsin-like serine proteinase that hydrolyzes the Phe8-His9 bond in angiotensin I (Ang I) to yield the octapeptide hormone angiotensin II (Ang II) and His-Leu, is the most specific, efficient Ang II-forming enzyme described. Leucine 184-187 angiotensinogen Homo sapiens 168-174 35255376-2 2022 Crosstalk between the foetal peptide hormones, angiotensin II (A-II) and vasopressin (AVP), and their degrading placental aminopeptidases (APs), aminopeptidase A for A-II and placental leucine aminopeptidase for both AVP and oxytocin, primarily regulate placental circulation. Leucine 185-192 angiotensinogen Homo sapiens 47-61 34460247-0 2021 Soybean-Derived Antihypertensive Peptide LSW (Leu-Ser-Trp) Antagonizes the Damage of Angiotensin II to Vascular Endothelial Cells through the Trans-vesicular Pathway. Leucine 46-49 angiotensinogen Homo sapiens 85-99 35255376-2 2022 Crosstalk between the foetal peptide hormones, angiotensin II (A-II) and vasopressin (AVP), and their degrading placental aminopeptidases (APs), aminopeptidase A for A-II and placental leucine aminopeptidase for both AVP and oxytocin, primarily regulate placental circulation. Leucine 185-192 angiotensinogen Homo sapiens 63-67 3290486-0 1988 Synthesis and renin inhibitory activity of angiotensinogen analogues having dehydrostatine, Leu psi [CH2S]Val, or Leu psi [CH2SO]Val at the P1-P1" cleavage site. Leucine 92-95 angiotensinogen Homo sapiens 43-58 3143009-2 1988 The synthesis of diol-containing renin inhibitors has revealed that a simple vicinal diol functionality corresponding to the scissile Leu-Val bond in human angiotensinogen is capable of imparting inhibitory activity at a comparable or higher level than either the corresponding aldehyde or hydroxymethyl functionality (compare inhibitors 2a-c or 3a-c). Leucine 134-137 angiotensinogen Homo sapiens 156-171 3290486-0 1988 Synthesis and renin inhibitory activity of angiotensinogen analogues having dehydrostatine, Leu psi [CH2S]Val, or Leu psi [CH2SO]Val at the P1-P1" cleavage site. Leucine 114-117 angiotensinogen Homo sapiens 43-58 3290486-1 1988 The synthesis and in vitro renin inhibitory potencies of angiotensinogen (ANG) analogues having amide (CONH) bond replacements at P1-P1", the Leu-Val cleavage site, corresponding to Leu psi[CH2SO]Val, and the trans olefinic analogue of statine (Sta), 4(S)-amino-6-methyl-2(E)-heptenoic acid (dehydrostatine, Dhs), are reported. Leucine 182-185 angiotensinogen Homo sapiens 57-72 3290486-1 1988 The synthesis and in vitro renin inhibitory potencies of angiotensinogen (ANG) analogues having amide (CONH) bond replacements at P1-P1", the Leu-Val cleavage site, corresponding to Leu psi[CH2SO]Val, and the trans olefinic analogue of statine (Sta), 4(S)-amino-6-methyl-2(E)-heptenoic acid (dehydrostatine, Dhs), are reported. Leucine 182-185 angiotensinogen Homo sapiens 74-77 3275777-1 1988 A structure-conformation-activity investigation of several angiotensinogen (ANG) based inhibitors of human renin modified by either Phe-Phe, Sta, Leu psi[CH2NH]Val, or Leu psi[CH(OH)CH2]Val at the P1-P1" clevage site and P5 Trp(Nin-For) (Ftr) was performed. Leucine 146-149 angiotensinogen Homo sapiens 59-74 3275777-1 1988 A structure-conformation-activity investigation of several angiotensinogen (ANG) based inhibitors of human renin modified by either Phe-Phe, Sta, Leu psi[CH2NH]Val, or Leu psi[CH(OH)CH2]Val at the P1-P1" clevage site and P5 Trp(Nin-For) (Ftr) was performed. Leucine 146-149 angiotensinogen Homo sapiens 76-79 2443571-1 1987 Using a high performance liquid chromatography assay that detects the cleavage of the C-terminal leucine from angiotensin I, we have identified a carboxypeptidase activity in mast cells from human lung and in dispersed mast cell preparations from human skin. Leucine 97-104 angiotensinogen Homo sapiens 110-123 3081342-6 1986 Both major forms have the same amino-terminal sequence, which includes that of ovine angiotensin I: Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu. Leucine 136-139 angiotensinogen Homo sapiens 85-98 2485065-3 1987 The minimal length for an effective substrate has been characterised as an octapeptide sequence derived from the amino terminal portion of angiotensinogen (residues 6----13): His-Pro-Phe-His-Leu-Val-Ile-His (Leu-Val is the scissile bond). Leucine 191-194 angiotensinogen Homo sapiens 139-154 2485065-3 1987 The minimal length for an effective substrate has been characterised as an octapeptide sequence derived from the amino terminal portion of angiotensinogen (residues 6----13): His-Pro-Phe-His-Leu-Val-Ile-His (Leu-Val is the scissile bond). Leucine 208-211 angiotensinogen Homo sapiens 139-154 3525438-2 1986 The crystal structure of the title compound, an analogue of the angiotensinogen-(10-13) peptide in which the N-terminal leucine and the C-terminal tyrosine are respectively replaced by the phenyloxy-acetic group and by phenylalanine, has been determined by X-ray diffraction. Leucine 120-127 angiotensinogen Homo sapiens 64-79 6385771-0 1984 Renin cleavage of a human kidney renin substrate analogous to human angiotensinogen, H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Ser-OH, that is human renin specific and is resistant to cathepsin D. Leucine 123-126 angiotensinogen Homo sapiens 68-83 3911093-4 1985 Cathepsin B hydrolyzed angiotensin I via a dipeptidyl carboxypeptidase mechanism removing His-Leu to form angiotensin II, and it degraded angiotensin II as an endopeptidase at the Val3-Tyr4 bond. Leucine 94-97 angiotensinogen Homo sapiens 23-36 6385771-1 1984 A synthetic tetradecapeptide, H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Ser-OH, which corresponds to the 13 amino terminal residues of human angiotensinogen plus a carboxy terminal serine to replace a suggested site of carbohydrate attachment, has been shown to be a good substrate for human kidney renin. Leucine 68-71 angiotensinogen Homo sapiens 153-168 207335-7 1978 A study of different substrates showed the activity to be highest with Z-Leu-Gly-Gly, followed by Z-Phe-His-Leu greater than bradykinin greater than Bz-Gly-Gly-Gly greater than Boc-Phe-Ala-Pro greater than Bz-Gly-His-Leu greater than angiotensin I. Leucine 73-76 angiotensinogen Homo sapiens 234-247 207335-7 1978 A study of different substrates showed the activity to be highest with Z-Leu-Gly-Gly, followed by Z-Phe-His-Leu greater than bradykinin greater than Bz-Gly-Gly-Gly greater than Boc-Phe-Ala-Pro greater than Bz-Gly-His-Leu greater than angiotensin I. Leucine 108-111 angiotensinogen Homo sapiens 234-247 6352693-7 1983 The enzyme was found to hydrolyze peptide bonds preferentially at the amino sides of hydrophobic amino acids such as Leu and Phe, when its specificity was studied using insulin B chain and angiotensin I. Leucine 117-120 angiotensinogen Homo sapiens 189-202